Ophthalmic manifestations of demyelination secondary to etanercept.
Do
Helen H-J
HH
Mohamed
Armin
A
Klistorner
Alexander
A
Grigg
John
J
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000150:complications*; D000068800:Etanercept; D005128:Eye Diseases / Q000209:etiology*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept